• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Insig

  2026-05-29

  EPI-001 is a small-molecule inhibitor targeting the androgen receptor N-terminal domain, validated for potent inhibition of AR transcriptional activity in prostate and triple-negative breast cancer (TNBC) models. Its unique mechanism disrupts both ligand-dependent and ligand-independent AR signaling, offering a distinct avenue for castration-resistant prostate cancer (CRPC) treatment research.

• NSC-23766: Rac GTPase Inhibitor for Advanced Cell Signaling

  2026-05-29

  NSC23766 trihydrochloride is a highly selective Rac GTPase inhibitor, enabling precise dissection of Rac1-driven signaling in cancer and metabolic research. Its workflow-friendly solubility, specificity for Rac1-GEF interactions, and validated efficacy in apoptosis and cell cycle modulation make it a standout tool for advanced experimental design.

• Targeting IL-6/GP130: Bazedoxifene’s Anticancer Mechanism Ex

  2026-05-28

  Shi et al. (2024) present a comprehensive analysis of bazedoxifene (BZA) as a novel inhibitor of the IL-6/GP130 signaling pathway, a key axis in tumor progression and therapy resistance. Their review elucidates BZA’s mechanism of action and its potential for repurposing in oncological clinical trials, highlighting implications for combinatorial regimens and targeted cancer therapy.

• Tiamulin as a Small-Molecule Inhibitor of TNF-α in Psoriasis

  2026-05-28

  This article examines recent evidence that Tiamulin (Thiamutilin), a pleuromutilin antibiotic, acts as a small-molecule inhibitor of TNF-α, demonstrating anti-inflammatory activity in models of psoriasis-like dermatitis. The findings address a translational gap in psoriasis therapeutics and provide mechanistic insight that expands Tiamulin's research applications beyond its established antimicrobial use.

• CIRT Induces Ferroptosis and M1 Polarization via DHODH Suppr

  2026-05-27

  The study by Wang and Cai (2025) uncovers how carbon-ion radiotherapy (CIRT) inhibits gastric cancer progression by inducing ferroptosis and promoting M1 macrophage polarization through the downregulation of DHODH. These mechanistic insights highlight DHODH as a promising therapeutic target to improve CIRT efficacy in resistant gastric tumors.

• Iptacopan (LNP023): Transforming Complement Pathway Research

  2026-05-27

  Explore how Iptacopan (LNP023), a potent oral factor B inhibitor, is redefining alternative pathway C3bBb inhibition and translational disease modeling. Delve into clinical and preclinical innovations that set this compound apart for complement activation research.

• Inhaled RNA Therapy Remodels Tumor Collagen for Lung Cancer

  2026-05-26

  This study introduces an inhalable lipid nanoparticle system for simultaneous delivery of anti-DDR1 mRNA and PD-L1 siRNA, directly targeting lung tumors. By disrupting collagen fiber alignment and counteracting immunosuppression, the approach enhances T cell infiltration and improves the efficacy of lung cancer immunotherapy.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Dr

  2026-05-26

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, more faithfully replicating tumor microenvironment heterogeneity. The model enables nuanced analysis of biomarker expression, transcriptomic changes, and drug response, offering a robust platform for personalized therapeutic research.

• LY2603618: Applied Chk1 Inhibitor Protocols in Cancer Resear

  2026-05-25

  LY2603618 empowers researchers to dissect G2/M checkpoint control and enhance DNA damage in cancer models, particularly non-small cell lung cancer. This guide translates bench-proven Chk1 inhibitor workflows, troubleshooting, and the latest findings on DNA repair into actionable protocols for APExBIO’s flagship tool.

• Poria cocos Polysaccharides Mitigate ALD via NRF2-Regulated

  2026-05-25

  This study demonstrates that Poria cocos polysaccharides (PCP) ameliorate alcoholic liver disease (ALD) by modulating ferroptosis through the NRF2 signaling pathway. The findings provide mechanistic insight into oxidative stress and ferroptosis regulation in ALD, highlighting NRF2 as a promising therapeutic target.

• GST-Mediated Resistance to Lambda-Cyhalothrin in M. usitatus

  2026-05-24

  Dong et al. (2024) demonstrate that glutathione S-transferase (GST) upregulation in Megalurothrips usitatus confers strong resistance to the insecticide lambda-cyhalothrin by enhancing antioxidant defenses. Inhibiting GST activity with diethyl maleate sharply increases insecticide sensitivity, providing mechanistic insight into oxidative stress regulation and resistance management.

• Ribotoxic Stress, UV-Induced Apoptosis, and ZAK Kinase Regul

  2026-05-23

  A recent study redefines the mechanism of UV-mediated cell death, identifying the ribotoxic stress response—driven by ribosome collisions and ZAK kinase activation—as the principal pathway, rather than canonical DNA damage signaling. This insight has important implications for apoptosis research, kinase pathway interrogation, and the design of targeted experimental models.

• Disodium Bicinchoninate in Cardiac and Molecular Assays

  2026-05-22

  Disodium bicinchoninate is redefining aqueous assay workflows with unmatched water solubility and chelation precision. Its value is particularly evident in cardiac fibrosis and cGMP/PKG pathway research, where organic-solvent-free protocols are essential for reproducibility and sensitivity.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-05-22

  This study uncovers how certain kinase inhibitors, by stabilizing inactive activation loop conformations, not only inhibit p38α MAP kinase but also promote its dephosphorylation by the PPM phosphatase WIP1. The findings reveal a structure-driven mechanism for dual-action inhibition, providing a new strategy for increasing potency and specificity in kinase-targeted research.

• LY2109761: Precision Modulation of Smad2/3 Signaling in Canc

  2026-05-21

  Explore how LY2109761, a potent TGF-β receptor type I and II dual inhibitor, enables precise control of Smad2/3 phosphorylation in advanced cancer and fibrosis research. This article uniquely bridges mechanistic insights with practical protocol guidance, highlighting evidence-backed strategies that set it apart from existing reviews.

14787 records 1/986 page Next 12345 下5页 Last page